Oryzon presents breakthroughs in LSD1 at US congress on new Alzheimer’s drugs
Lysine Specific Demethylase 1 (LSD1) is a pharmacological target for new approaches to treating cancer and neurodegenerative and viral diseases.
By Biocat
Oryzon Genomics will participate in the scientific program of the 14th International Conference on Alzheimer’s Drug Discovery, on 9 September in New Jersey (United States), where global breakthroughs to accelerate the development of innovative treatments for Alzheimer’s, related dementia and cognitive ageing will be debated.
As part of the session on neuroprotection and synaptic plasticity at this congress, co-founder and CSO of Oryzon Tamara Maes will give an presentation entitled LSD1-MAOB Inhibitors as Disease Modifying Drugs for Alzheimer's Disease, on the results they have obtained in animal models for the drug candidate they are developing, which is currently in the preclinical phase. The congress brings together scientists from the academic arena and industry. Merck, Pfizer and Lilly are sponsoring the event.
Inhibiting the LSD1-MAOB protein plays a key role in regulating the expression of genes that neurons need to stay active, as well as in the progression of Alzheimer’s and other neurological disorders like Parkinson’s and Huntington’s. Oryzon is one of the leading global biotechnology companies in LSD inhibitor molecules, especially LSD 1, and has nearly 900 molecules protected under 18 patents. They have an exclusive platform to identify epigenetic targets, a very new field with great projection for the future.
In 2011, Oryzon received a €300,000 grant from the Alzheimer's Drug Discovery Foundation —the body organizing this congress— to research new therapies for Alzheimer’s.